Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2026-09-15 16:30:04 ET · period of report 2026-09-14 · accession 0001193125-26-391985 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 16:30 | 2026-09-14 | NAMS | Davidson Michael H. | CEO, Dir | P - Purchase | $22.65 | +10.0K | 792.9K | +1% | +$226.5K |
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-09-14 | P | A | 10,000 | $22.65 | 792,923 | D | — | — | (F1) Includes 163,352 ordinary shares subject to restricted stock unit awards that remain subject to vesting. (F2) Reflects the prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned by the Reporting Person. Such ordinary shares were previously held of record by Stichting Administratiekantoor EPNAP for the benefit of the Reporting Person. |